Storytelling ist die innovativste und erfolgversprechendste Methode, um Kundenbeziehungen zu verbessern, Mitarbeiter zu begeistern, für die Imagekommunikation und Selbstdarstellung erfolgreicher Unternehmen. Immer mehr Führungskräfte, Mitarbeiter, Freiberufler und Selbstständige arbeiten mit Geschichten. Denn mit Geschichten können sie ihre Ziele wesentlich überzeugender und lebendiger transportieren als mit trockenen Monatsberichten und dürren Fakten. Allerdings müssen es gute Geschichten sein. Doch wie macht man Geschichten spannend und interessant? Wie stellt man sicher, dass sie wirklich die richtigen Botschaften vermitteln? Wie setzt man Höhepunkte, überrascht die Zuhörer, schlägt sie in seinen Bann? Wer dieses Lern- und Arbeitsbuch gelesen hat, kann andere mitreißen und überzeugen - mit Geschichten, die ankommen. Viele Beispiele, Checklisten und Übungen helfen dabei.

Abstract: OBJECTIVES Cytoreductive surgery and hyperthermic intrathoracic chemotherapy (HITOC) is effective on survival for patients with pleural metastatic thymic tumours. METHODS Multicentre, retrospective analysis of patients with stage IVa thymic tumours treated with surgical resection and HITOC. Primary end point was overall survival, secondary end points were recurrence-/progression-free survival and morbidity/mortality. RESULTS A total of n = 58 patients (thymoma, n = 42; thymic carcinoma, n = 15; atypical carcinoid of the thymus, n = 1) were included, who had primary pleural metastases (n = 50; 86%) or pleural recurrence (n = 8; 14%). Lung-preserving resection (n = 56; 97%) was the preferred approach. Macroscopically complete tumour resection was achieved in n = 49 patients (85%). HITOC was performed with cisplatin alone (n = 38; 66%) or in combination with doxorubicin (n = 20; 34%). Almost half of the patients (n = 28; 48%) received high-dose cisplatin > 125 mg/m2 body surface area. Surgical revision was required in 8 (14%) patients. In-hospital mortality rate was 2%. During follow-up, tumour recurrence/progression was evident in n = 31 (53%) patients. Median follow-up time was 59 months. The 1-, 3- and 5-year survival rates were 95%, 83% and 77%, respectively. Recurrence/progression-free survival rates were 89%, 54% and 44%, respectively. Patients with thymoma had significantly better survival compared to patients with thymic carcinoma (P-value ≤0.001). CONCLUSIONS Promising survival rates in patients with pleural metastatic stage IVa in thymoma (94%) and even in thymic carcinoma (41%) were achieved. Surgical resection and HITOC is safe and effective for treatment of patients with pleural metastatic thymic tumours stage IVa